Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: A randomized double-blind pilot trial

Matthew J. Byerly, Paul A. Nakonezny, A. John Rush

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

This study evaluated the effect of switching to quetiapine vs. risperidone continuation on sexual functioning in outpatients with risperidone-associated sexual dysfunction. Outpatients (n = 42, age ≥ 18 years) with schizophrenia or schizoaffective disorder who experienced risperidone-associated sexual dysfunction were randomized to 6 weeks of double-blind risperidone continuation (mean dose = 4.1 mg/day, S.D. = 1.2) or quetiapine switch (mean dose = 290.0 mg/day, S.D. = 55.2) treatment. The five-item Arizona Sexual Experience Scale (ASEX) assessed sexual functioning at baseline and subsequently at weeks 2, 4 and 6. A mixed-model analysis of repeated measures included gender and baseline ASEX and PANSS scores as covariates. There was no significant Treatment Group effect for ASEX total scores and ASEX sub-items, and no significant Treatment Group × Period interaction for ASEX total scores and ASEX sub-items. Treatment Group effects were not significantly different in any of the prospective weeks for ASEX total scores and ASEX sub-items. Adjusted mean ASEX total scores were slightly lower in the quetiapine switch group than in the risperidone continuation group at weeks 2 and 6 (21.27 vs. 22.18 and 18.51 vs. 20.53, respectively), but were nearly identical at week 4 (20.01 vs. 20.15). In this pilot trial, sexual functioning did not differ significantly between outpatients receiving quetiapine switch vs. risperidone continuation, although the quetiapine switch group had slightly lower adjusted mean ASEX total scores at weeks 2 and 6.

Original languageEnglish (US)
Pages (from-to)115-120
Number of pages6
JournalPsychiatry Research
Volume159
Issue number1-2
DOIs
StatePublished - May 30 2008

Fingerprint

Risperidone
Psychotic Disorders
Schizophrenia
Outpatients
Quetiapine Fumarate
Therapeutics

Keywords

  • Antipsychotic
  • Atypical
  • Double-blind
  • Quetiapine
  • Randomized
  • Risperidone
  • Sexual dysfunction

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry
  • Psychology(all)

Cite this

@article{5708ccec229b419e9495dbb49221cde2,
title = "Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: A randomized double-blind pilot trial",
abstract = "This study evaluated the effect of switching to quetiapine vs. risperidone continuation on sexual functioning in outpatients with risperidone-associated sexual dysfunction. Outpatients (n = 42, age ≥ 18 years) with schizophrenia or schizoaffective disorder who experienced risperidone-associated sexual dysfunction were randomized to 6 weeks of double-blind risperidone continuation (mean dose = 4.1 mg/day, S.D. = 1.2) or quetiapine switch (mean dose = 290.0 mg/day, S.D. = 55.2) treatment. The five-item Arizona Sexual Experience Scale (ASEX) assessed sexual functioning at baseline and subsequently at weeks 2, 4 and 6. A mixed-model analysis of repeated measures included gender and baseline ASEX and PANSS scores as covariates. There was no significant Treatment Group effect for ASEX total scores and ASEX sub-items, and no significant Treatment Group × Period interaction for ASEX total scores and ASEX sub-items. Treatment Group effects were not significantly different in any of the prospective weeks for ASEX total scores and ASEX sub-items. Adjusted mean ASEX total scores were slightly lower in the quetiapine switch group than in the risperidone continuation group at weeks 2 and 6 (21.27 vs. 22.18 and 18.51 vs. 20.53, respectively), but were nearly identical at week 4 (20.01 vs. 20.15). In this pilot trial, sexual functioning did not differ significantly between outpatients receiving quetiapine switch vs. risperidone continuation, although the quetiapine switch group had slightly lower adjusted mean ASEX total scores at weeks 2 and 6.",
keywords = "Antipsychotic, Atypical, Double-blind, Quetiapine, Randomized, Risperidone, Sexual dysfunction",
author = "Byerly, {Matthew J.} and Nakonezny, {Paul A.} and Rush, {A. John}",
year = "2008",
month = "5",
day = "30",
doi = "10.1016/j.psychres.2007.02.014",
language = "English (US)",
volume = "159",
pages = "115--120",
journal = "Psychiatry Research",
issn = "0165-1781",
publisher = "Elsevier Ireland Ltd",
number = "1-2",

}

TY - JOUR

T1 - Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder

T2 - A randomized double-blind pilot trial

AU - Byerly, Matthew J.

AU - Nakonezny, Paul A.

AU - Rush, A. John

PY - 2008/5/30

Y1 - 2008/5/30

N2 - This study evaluated the effect of switching to quetiapine vs. risperidone continuation on sexual functioning in outpatients with risperidone-associated sexual dysfunction. Outpatients (n = 42, age ≥ 18 years) with schizophrenia or schizoaffective disorder who experienced risperidone-associated sexual dysfunction were randomized to 6 weeks of double-blind risperidone continuation (mean dose = 4.1 mg/day, S.D. = 1.2) or quetiapine switch (mean dose = 290.0 mg/day, S.D. = 55.2) treatment. The five-item Arizona Sexual Experience Scale (ASEX) assessed sexual functioning at baseline and subsequently at weeks 2, 4 and 6. A mixed-model analysis of repeated measures included gender and baseline ASEX and PANSS scores as covariates. There was no significant Treatment Group effect for ASEX total scores and ASEX sub-items, and no significant Treatment Group × Period interaction for ASEX total scores and ASEX sub-items. Treatment Group effects were not significantly different in any of the prospective weeks for ASEX total scores and ASEX sub-items. Adjusted mean ASEX total scores were slightly lower in the quetiapine switch group than in the risperidone continuation group at weeks 2 and 6 (21.27 vs. 22.18 and 18.51 vs. 20.53, respectively), but were nearly identical at week 4 (20.01 vs. 20.15). In this pilot trial, sexual functioning did not differ significantly between outpatients receiving quetiapine switch vs. risperidone continuation, although the quetiapine switch group had slightly lower adjusted mean ASEX total scores at weeks 2 and 6.

AB - This study evaluated the effect of switching to quetiapine vs. risperidone continuation on sexual functioning in outpatients with risperidone-associated sexual dysfunction. Outpatients (n = 42, age ≥ 18 years) with schizophrenia or schizoaffective disorder who experienced risperidone-associated sexual dysfunction were randomized to 6 weeks of double-blind risperidone continuation (mean dose = 4.1 mg/day, S.D. = 1.2) or quetiapine switch (mean dose = 290.0 mg/day, S.D. = 55.2) treatment. The five-item Arizona Sexual Experience Scale (ASEX) assessed sexual functioning at baseline and subsequently at weeks 2, 4 and 6. A mixed-model analysis of repeated measures included gender and baseline ASEX and PANSS scores as covariates. There was no significant Treatment Group effect for ASEX total scores and ASEX sub-items, and no significant Treatment Group × Period interaction for ASEX total scores and ASEX sub-items. Treatment Group effects were not significantly different in any of the prospective weeks for ASEX total scores and ASEX sub-items. Adjusted mean ASEX total scores were slightly lower in the quetiapine switch group than in the risperidone continuation group at weeks 2 and 6 (21.27 vs. 22.18 and 18.51 vs. 20.53, respectively), but were nearly identical at week 4 (20.01 vs. 20.15). In this pilot trial, sexual functioning did not differ significantly between outpatients receiving quetiapine switch vs. risperidone continuation, although the quetiapine switch group had slightly lower adjusted mean ASEX total scores at weeks 2 and 6.

KW - Antipsychotic

KW - Atypical

KW - Double-blind

KW - Quetiapine

KW - Randomized

KW - Risperidone

KW - Sexual dysfunction

UR - http://www.scopus.com/inward/record.url?scp=42749092665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42749092665&partnerID=8YFLogxK

U2 - 10.1016/j.psychres.2007.02.014

DO - 10.1016/j.psychres.2007.02.014

M3 - Article

C2 - 18295343

AN - SCOPUS:42749092665

VL - 159

SP - 115

EP - 120

JO - Psychiatry Research

JF - Psychiatry Research

SN - 0165-1781

IS - 1-2

ER -